International Isotopes posts growth, strong margins but still loss‑making; $12.5M sale contingent

Snapshot - International Isotopes Inc. (OTCMKTS: INIS)

What's happening inside the company
International Isotopes is running its five core segments (Theranostics, Cobalt, Nuclear Medicine Standards, Medical Devices, Fluorine). Management is prioritizing core revenue-producing segments while investing to scale Medical Devices and global distribution (China JV, PhanQual). The company has an outstanding asset sale agreement for the Fluorine / De‑Conversion project that would generate $12.5M on closing (Outside Date: March 31, 2026) but closing is contingent on buyer financing and approvals.

Key points & statistics (facts from Q2 / six months ended June 30, 2025)
- Total sales (Q2 2025): $3,655,320; Six months: $6,894,220.
- Gross profit (Q2 2025): $2,141,559 (gross margin Q2: 59%); Six months gross profit: $4,173,596 (gross margin six months: 61%).
- Net loss (Q2 2025): $(160,785); Net loss (six months): $(273,479) - improved vs. six months 2024 $(387,496).
- Operating expenses (Q2 2025): $2,276,400; Salaries/contract labor Q2: $1,088,832; G&A Q2: $1,084,907; R&D Q2: $102,661.
- Cash & cash equivalents (6/30/2025): $1,859,424; Restricted cash: $1,462,280; Total cash + restricted per cash flow statement: $3,321,704.
- Total assets: $17,510,099; Total liabilities: $13,244,217; Stockholders' equity: $4,265,882 (6/30/2025).
- Common shares outstanding: 528,010,308 (issued & outstanding at 6/30/2025); 528,104,105 shares outstanding reported as of Aug 8, 2025.
- Mandatorily redeemable convertible preferred stock: 4,063 shares; liability value $4,063,000; accrues 6% dividends (dividends for six months: $243,780).
- Current unearned revenue (6/30/2025): $568,816 (cobalt contracts with multi‑year cycles).
- Customer concentration: top three customers ≈32% of gross revenue (six months); one customer ≈18% of revenue.
- Segment highlights Q2 vs prior year: Nuclear Medicine Standards sales +149% (Q2), Theranostics sales down 12% (Q2), Cobalt sales +14% (Q2).
- Notable liabilities / debt accruals (6/30/2025): accrued interest on 2013 promissory note $346,734; 2019 note accrued interest $219,131; 2018 note accrued interest $51,770. Subsequent event: August 2025 extensions moved several promissory note maturities to March 31, 2028.

Positive aspects of the income statement
- Revenue growth: consolidated sales increased ~15% year‑over‑year for the quarter and ~14% for six months, driven largely by Nuclear Medicine Standards recovery and sales gains.
- Gross margins strong: Q2 gross margin ~59% and six‑month margin ~61% - healthy for manufacturing/distribution of radiopharma and standards.
- Improved profitability trend: six‑month net loss narrowed from $(387,496) in 2024 to $(273,479) in 2025; operating cash provided improved (six months cash from ops $310,446 vs $288,597 prior year).
- Cash generation from operations: positive operating cash flow ($310,446) despite a GAAP net loss - indicates working capital and noncash adjustments are helping liquidity.
- Strategic deals and JV activity (China JV, PhanQual) support international scaling and distribution opportunities.

Negative aspects of the income statement / risks
- Continued GAAP losses: company still reporting net losses (Q2 and six months) - not yet consistently profitable on GAAP basis.
- Operating costs remain elevated: salaries, G&A and start‑up costs (Medical Devices) pressuring segment results; Medical Device segment incurred large development losses (Q2 net loss $201,305; six months net loss $382,974).
- One‑time / segment hits: Cobalt Products suffered a $129,000 waste disposal expense that swung the segment to a loss (Cobalt Q2 net loss $(97,040)).
- Revenue concentration and supply-chain risk: top three customers ≈32% of revenue; supply outages (recent Gadolinium‑153 outage) can materially impact sales - cobalt production is also dependent on DOE supply / ATR access.
- Liquidity & capital structure concerns: significant long‑term liabilities ($10.1M long‑term liabilities), series C preferred recorded as a $4.063M liability with mandatory redemption (Feb 28, 2027) and dividend accruals; reliance on potential $12.5M Fluorine sale that is uncertain and conditional.
- Rising receivables and modest cash decline: accounts receivable increased to $1.732M; cash & equivalents decreased slightly from Dec 31, 2024 to June 30, 2025 (from $1.945M to $1.859M).
- Customer/product timing: cobalt revenue is lumpy (large infrequent sales) causing volatile period‑to‑period results.

Near‑term watch list / catalysts
- Fluorine/de‑conversion asset sale: $12.5M potential proceeds if closed by Outside Date March 31, 2026 - buyer requested extension but company held the date; closing depends on buyer financing and NRC approvals.
- Supply restoration/stability: monitoring Gd‑153 and other isotope availability and DOE arrangements for cobalt feedstock - supply shocks materially change revenue.
- Medical Device commercialization: timing and cost of rolling out acquired AMICI products (RadVent) and EasyFill system; delays (tariff issues) pushed certain product releases into 2026 - continued development spending will weigh on near‑term earnings.
- Debt and preferred stock timing: mandatory preferred redemption and promissory note maturities / extensions; continued access to financing or stock issuances could dilute shareholders or alter capital structure.
- Execution of international JV (China) and PhanQual to expand manufacturing/distribution - if successful, could materially increase recurring revenue from Theranostics and Standards.

Bottom line: International Isotopes shows healthy gross margins and top‑line growth driven by Nuclear Medicine Standards, while still investing heavily in Medical Devices and absorbing one‑off costs (waste disposal). The company has positive operating cash flow but remains loss‑making on GAAP basis and exposed to supply and customer concentration risks. The $12.5M contingent Fluorine asset sale and successful JV executions are the main upside catalysts; debt/preferred obligations and supply/customer concentration are the main near‑term risks to monitor.